L
Lunit
AI-powered medical solutions for cancer diagnostics and therapeutics
About Lunit
Lunit.io is a groundbreaking startup that operates in the healthcare technology sector, specifically focusing on the application of artificial intelligence (AI) in cancer detection and treatment. The company's primary mission is to increase the survival rate of cancer patients by enabling early-stage detection and accurately predicting treatment response.
Lunit.io's AI technology serves a broad range of clients, including hospitals, research institutions, and healthcare providers. A notable example is Inje University Paik Hospital, which has introduced Lunit's AI nationwide. The company's business model revolves around providing AI solutions that can be integrated into existing healthcare systems to enhance their diagnostic and treatment capabilities.
The company generates revenue by selling its AI solutions to healthcare providers. These solutions help in detecting early-stage cancers, which allows for timely management and increases the chances of survival. Additionally, by accurately predicting treatment response, Lunit's AI helps in increasing the efficacy of immunotherapy, a type of cancer treatment that uses the body's immune system to fight cancer.
Lunit.io has been recognized for its innovative approach, ranking first place in the CAMELYON Grand Challenge 2017, a competition focused on AI applications in healthcare. The company also boasts a strong network of global research and business partners, including prominent figures like Kyung Hyun Cho, Interim Deputy Director at the Center for Data Science New York University, and Helmy Eltoukhy, CEO of Guardant Health.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2022
Open roles
Lunit in the Seoul ecosystem
The Lunit office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A5 investors entered at this stage
SBVA
Formation 8
Mirae Asset Venture Investment
InterVest
KT Investment
Series B and later10 investors entered at this stage
Shinhan Invest
Legend Capital
Shinhan Investment Corporation
IMM Investment
Guardant Health
Casdin Capital
NSG Ventures
Tybourne Capital Management
HealthQuest Capital
BrightEdge
Source: Dealroom Talent Intelligence.
Patents
137 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Lunit on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Lunit swaps high-interest debt for $35.6M in new convertible bonds
Prova.ai raises $1.2M to predict ovarian cancer from mammograms


